Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Missouri meth bills

This article was originally published in The Tan Sheet

Executive Summary

Retail display of single-ingredient OTCs containing ephedrine, pseudoephedrine, or phenylpropanolamine would be limited to behind the counter or within six feet of a checkout register in stores without anti-theft systems under Missouri House Bill 470. Bill passed state assembly April 8, was referred to Senate Judiciary Committee, where an April 23 hearing is scheduled. Intended to limit availability of methamphetamine ingredients, bill also would block sales of more than six grams, or two packages, of any of the products. Senate Bill 442, also awaiting a hearing, includes ban on more than six grams of products and might incorporate other elements of HB 470. In testimony before Missouri Senate, CHPA has claimed bill will unduly restrict retailers without significant impact on crime, association says...

You may also be interested in...

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 


Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts